Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the effectiveness of drugs currently on the market to treat acute myeloid leukemia (AML) at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX. Dr Perl explains how the FLT3 inhibitors midostaurin and quizartinib have improved the overall survival of AML patients, and protect against relapse better than standard therapy. With tolerable side effects, he excitedly disccusses the the future of AML treatments which do not affect the patient’s day to day life.
Midostaurin and quizartinib: improving survival and day-to-day life in AML
